tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PHVS Stock Latest News

Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
RatingsPharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
1d ago
PHVS
Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
PremiumRatings
Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
1d ago
PHVS
Pharvaris presents data supporting ongoing clinical development of deucrictibant
PremiumThe Fly
Pharvaris presents data supporting ongoing clinical development of deucrictibant
4d ago
PHVS
Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability
PremiumRatings
Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability
23d ago
PHVS
Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target
PremiumRatings
Pharvaris’s Promising Pipeline Progress and Strong Financial Position Justify Buy Rating with $43 Target
23d ago
PHVS
Pharvaris price target raised to $27 from $25 at Wedbush
PremiumThe FlyPharvaris price target raised to $27 from $25 at Wedbush
23d ago
PHVS
Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
Premium
The Fly
Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
23d ago
PHVS
Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
Premium
Ratings
Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
24d ago
PHVS
Pharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
PremiumThe Fly
Pharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
24d ago
PHVS
Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
PremiumCompany Announcements
Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
24d ago
6K
PHVS
Pharvaris initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Pharvaris initiated with an Overweight at Cantor Fitzgerald
1M ago
PHVS
Pharvaris initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Pharvaris initiated with an Overweight at Cantor Fitzgerald
1M ago
PHVS
Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
PremiumRatingsPharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
2M ago
PHVS
Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
Premium
Ratings
Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
2M ago
PHVS
Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
Premium
Ratings
Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
2M ago
PHVS
Pharvaris Reports 2024 Financial Results and Business Progress
PremiumCompany Announcements
Pharvaris Reports 2024 Financial Results and Business Progress
2M ago
PHVS
Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion
PremiumRatings
Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion
2M ago
PHVS
Trump threatens even higher tariffs on China after retaliation: Morning Buzz
PremiumThe Fly
Trump threatens even higher tariffs on China after retaliation: Morning Buzz
2M ago
DG
GM
Pharvaris Reports 2024 Financial Results and Advances HAE Treatment Studies
PremiumCompany Announcements
Pharvaris Reports 2024 Financial Results and Advances HAE Treatment Studies
2M ago
6K
PHVS
Pharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last year
PremiumThe FlyPharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last year
2M ago
PHVS
Pharvaris says EC grants orphan designation to deucrictibant
Premium
The Fly
Pharvaris says EC grants orphan designation to deucrictibant
2M ago
PHVS
Pharvaris reports safety and efficacy data of deucrictibant
Premium
The Fly
Pharvaris reports safety and efficacy data of deucrictibant
3M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >